Saniona AB (CHIX:SANIOS) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:SANIOS Saniona AB CHIX:SANIOS
34 GF Score
Price kr11.84
GF Value kr25.79
! 1 Warning Sign
View Full Analysis

What is Saniona AB Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

CHIX:SANIOS
34GF Score
Saniona AB CHIX:SANIOS
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Saniona AB (CHIX:SANIOS) Overvalued in 2026?

Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued. The current stock price of kr11.84 is trading 54.1% below its estimated GF Value™ of kr25.79.

Key valuation signals for CHIX:SANIOS:

  • Interest Expense (Positive):
  • GF Value™: kr25.79 vs. price of kr11.84 (54.1% below fair value)
  • GF Score™: 34/100 with 1 warning sign

No single metric tells the full story. See the CHIX:SANIOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Saniona AB Business Description

Address Murervangen 42, Glostrup, DNK, DK-2600
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
34GF Score

Get the complete analysis for CHIX:SANIOS

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr11.84
Price
kr25.79
GF Value